Literature DB >> 3044982

Influence of tuftsin-like synthetic peptides derived from C-reactive protein (CRP) on platelet behaviour.

B A Fiedel1.   

Abstract

C-reactive protein (CRP) is an acute-phase reactant that modifies platelet function differently, depending upon its physiochemical state. Aggregated and ligand-complexed forms of CRP initiate the activation of platelets, whereas naturally occurring CRP peptides inhibit platelet activation. The present study documents neutral proteases of the polymorphonuclear leucocyte (PMN) to cleave CRP into reaction products with the potential to inhibit platelet activation, and explore the structure-function relationships involved in the regulation of platelet activation by CRP using synthetic CRP peptides. Evidence was obtained that (i) a minimum of two linear functional domains exist within CRP that influence platelet activation; (ii) they reside in the mid-portion and at the C-terminus of the CRP molecule; (iii) the mid-portion domain inhibits platelet activation stimulated by adenosine diphosphate (ADP) or acid-soluble collagen, whereas the C-terminal domain initiates platelet activation; (iv) the functional expression of the C-terminal domain is maximized when the linear peptide is immobilized on latex; and (v) both CRP domains contain a homologue of the immunoregulatory signal peptide, tuftsin. These data suggest that the molecular mechanisms by which platelet processes are modulated by CRP may be related to the presence of tuftsin homologues in CRP.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3044982      PMCID: PMC1385063     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  19 in total

1.  Genomic DNA sequence for human C-reactive protein.

Authors:  K J Lei; T Liu; G Zon; E Soravia; T Y Liu; N D Goldman
Journal:  J Biol Chem       Date:  1985-10-25       Impact factor: 5.157

Review 2.  Acute phase proteins with special reference to C-reactive protein and related proteins (pentaxins) and serum amyloid A protein.

Authors:  M B Pepys; M L Baltz
Journal:  Adv Immunol       Date:  1983       Impact factor: 3.543

3.  Synthetic peptide with cell attachment activity of fibronectin.

Authors:  M Pierschbacher; E G Hayman; E Ruoslahti
Journal:  Proc Natl Acad Sci U S A       Date:  1983-03       Impact factor: 11.205

Review 4.  C-reactive protein and the acute phase response.

Authors:  H Gewurz; C Mold; J Siegel; B Fiedel
Journal:  Adv Intern Med       Date:  1982

5.  Activation of platelets by modified C-reactive protein.

Authors:  B A Fiedel; R M Simpson; H Gewurz
Journal:  Immunology       Date:  1982-03       Impact factor: 7.397

6.  Generation of thromboxane A2 and aorta-contracting activity from platelets stimulated with modified C-reactive protein.

Authors:  R M Simpson; A Prancan; J M Izzi; B A Fiedel
Journal:  Immunology       Date:  1982-09       Impact factor: 7.397

7.  Characterization of genomic and complementary DNA sequence of human C-reactive protein, and comparison with the complementary DNA sequence of serum amyloid P component.

Authors:  P Woo; J R Korenberg; A S Whitehead
Journal:  J Biol Chem       Date:  1985-10-25       Impact factor: 5.157

8.  Inhibition of platelet adhesion to fibronectin, fibrinogen, and von Willebrand factor substrates by a synthetic tetrapeptide derived from the cell-binding domain of fibronectin.

Authors:  D M Haverstick; J F Cowan; K M Yamada; S A Santoro
Journal:  Blood       Date:  1985-10       Impact factor: 22.113

9.  Further studies on the modulation of blood coagulation by human serum amyloid P component and its acute phase homologue C-reactive protein.

Authors:  B A Fiedel; C S Ku
Journal:  Thromb Haemost       Date:  1986-06-30       Impact factor: 5.249

10.  Effect of C-reactive protein on platelet-activating factor-induced platelet aggregation and membrane stabilization.

Authors:  C Vigo
Journal:  J Biol Chem       Date:  1985-03-25       Impact factor: 5.157

View more
  4 in total

1.  The role of hemostasis in infective endocarditis.

Authors:  Emanuele Durante-Mangoni; Rosa Molaro; Domenico Iossa
Journal:  Curr Infect Dis Rep       Date:  2014-11       Impact factor: 3.725

2.  Pentraxin binding to isolated rat liver nuclei.

Authors:  E G Shephard; P J Smith; S Coetzee; A F Strachan; F C de Beer
Journal:  Biochem J       Date:  1991-10-01       Impact factor: 3.857

3.  ITF1697, a stable Lys-Pro-containing peptide, inhibits weibel-palade body exocytosis induced by ischemia/reperfusion and pressure elevation.

Authors:  Silvia Bertuglia; Hideo Ichimura; Gianluca Fossati; Kaushik Parthasarathi; Flavio Leoni; Daniela Modena; Piero Cremonesi; Jahar Bhattacharya; Paolo Mascagni
Journal:  Mol Med       Date:  2007 Nov-Dec       Impact factor: 6.354

4.  Fine mapping of the human pentraxin gene region on chromosome 1q23.

Authors:  M T Walsh; A Divane; A S Whitehead
Journal:  Immunogenetics       Date:  1996       Impact factor: 2.846

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.